Wolfe Research Reiterates Outperform on ZoomInfo Technologies, Lowers Price Target to $30

Wolfe Research analyst Alex Zukin reiterates ZoomInfo Technologies (NASDAQ:ZI) with a Outperform and lowers the price target from $37 to $30.

byBenzinga Newsdesk

February 7, 2023

1 minute read

Wolfe Research analyst Alex Zukin reiterates ZoomInfo Technologies (NASDAQ:ZI) with a Outperform and lowers the price target from $37 to $30.

Scholar Rock Presents Exploratory Responder Analysis On Efficacy Data From Apitegromab TOPAZ Phase 2 Trial At Child Neurology Society Annual Meeting

By Benzinga Newsdesk

September 30, 11:45 AM

Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a late breaker poster

SRRK

Masonite International Q3 Adj. EPS $1.99 Beats $1.87 Estimate, Sales $652.21M Miss $675.04M Estimate; Sees FY21 Adj. EPS $7.95-$8.25 vs $8.13 Estimate, Adj. EBITDA $415M-$425M

By Benzinga Newsdesk

November 8, 6:17 PM

Masonite International (NYSE:DOOR) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $1.87 by 6.42 percent. This is a 7.87 percent decrease over earnings of $2.16 per share from

DOOR

Novartis Earlier Launched New $11B Share Buyback Program

By Charles Gross

March 13, 5:15 AM

-Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-launches-new-share-buyback-up-10-its-stock-2023-03-13/

NVS

Inhibrx Q2 EPS $(0.55) Up From $(0.99) YoY

By Benzinga Newsdesk

August 9, 5:23 PM

Inhibrx (NASDAQ:INBX) reported quarterly losses of $(0.55) per share. This is a 44.44 percent increase over losses of $(0.99) per share from the same period last year.

INBX

Wolfe Research Reiterates Outperform on ZoomInfo Technologies, Lowers Price Target to $30

Related Posts

Scholar Rock Presents Exploratory Responder Analysis On Efficacy Data From Apitegromab TOPAZ Phase 2 Trial At Child Neurology Society Annual Meeting

Masonite International Q3 Adj. EPS $1.99 Beats $1.87 Estimate, Sales $652.21M Miss $675.04M Estimate; Sees FY21 Adj. EPS $7.95-$8.25 vs $8.13 Estimate, Adj. EBITDA $415M-$425M

Novartis Earlier Launched New $11B Share Buyback Program

Inhibrx Q2 EPS $(0.55) Up From $(0.99) YoY